Other research analysts also recently issued reports about the company. Citigroup reiterated a buy rating and issued a GBX 2,250 ($29.40) price target on shares of Hikma Pharmaceuticals in a report on Tuesday, October 30th. Jefferies Financial Group raised shares of Hikma Pharmaceuticals to a buy rating and boosted their price objective for the company from GBX 1,643 ($21.47) to GBX 2,000 ($26.13) in a research note on Tuesday, November 27th. Barclays raised shares of Hikma Pharmaceuticals to an equal weight rating and boosted their price objective for the company from GBX 1,400 ($18.29) to GBX 1,800 ($23.52) in a research note on Tuesday, November 6th. Numis Securities reissued a hold rating on shares of Hikma Pharmaceuticals in a research note on Wednesday, August 15th. Finally, JPMorgan Chase & Co. reissued a neutral rating and set a GBX 1,050 ($13.72) price objective on shares of Hikma Pharmaceuticals in a research note on Tuesday, August 21st. Five research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Hikma Pharmaceuticals currently has a consensus rating of Hold and an average price target of GBX 1,815.71 ($23.73).
HIK traded up GBX 35 ($0.46) during trading on Thursday, hitting GBX 1,722.50 ($22.51). The company’s stock had a trading volume of 149,935 shares, compared to its average volume of 822,138. Hikma Pharmaceuticals has a twelve month low of GBX 814.20 ($10.64) and a twelve month high of GBX 2,346 ($30.65).
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products.
Further Reading: The Discount Rate – What You Need to Know
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.